TADLIQ Drug Patent Profile

Which patents cover Tadliq, and what generic alternatives are available?

Tadliq is a drug marketed by Cmp Dev Llc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in nine countries.

The generic ingredient in TADLIQ is tadalafil. There are twenty-five drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the tadalafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tadliq

A generic version of TADLIQ was approved as tadalafil by TEVA PHARMS USA on May 22^nd, 2018.

Summary for TADLIQ

International Patents:	9
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	7,070
Drug Prices:	Drug price information for TADLIQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TADLIQ
What excipients (inactive ingredients) are in TADLIQ?	TADLIQ excipients list
DailyMed Link:	TADLIQ at DailyMed

See drug prices for TADLIQ

Pharmacology for TADLIQ

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Paragraph IV (Patent) Challenges for TADLIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TADLIQ	Oral Suspension	tadalafil	20 mg/5 mL	214522	1	2025-12-03

US Patents and Regulatory Information for TADLIQ

TADLIQ is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,975,006		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,666,576		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	12,186,322		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,382,917		Y

EU/EMA Drug Approvals for TADLIQ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Limited	Talmanco (previously Tadalafil Generics)	tadalafil	EMEA/H/C/004297Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.	Authorised	yes	no	no	2017-01-09
Eli Lilly Nederland B.V.	Tadalafil Lilly	tadalafil	EMEA/H/C/004666Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.	Authorised	no	no	no	2017-03-22
Eli Lilly Nederland B.V.	Adcirca (previously Tadalafil Lilly)	tadalafil	EMEA/H/C/001021AdultsTreatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.Paediatric populationTreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III.	Authorised	no	no	no	2008-10-01
Eli Lilly Nederland B.V.	Cialis	tadalafil	EMEA/H/C/000436Treatment of erectile dysfunction.In order for tadalafil to be effective, sexual stimulation is required.Cialis is not indicated for use by women.	Authorised	no	no	no	2002-11-12

International Patents for TADLIQ

See the table below for patents covering TADLIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018397436	Liquid oral formulations for PDE V inhibitors
Brazil	112020012986	formulações orais líquidas para inibidores de pde v
Canada	3086881	FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)
China	111683683	PDE V抑制剂的液体口服制剂 (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)

Supplementary Protection Certificates for TADLIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0740668	PA2003001	Lithuania		PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
0740668	SPC/GB03/007	United Kingdom		PRODUCT NAME: TADALAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF.; REGISTERED: UK EU/1/02/237/001-004 20021114
0740668	PA2003001,C0740668	Lithuania		PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
0740668	C00740668/01	Switzerland		PRODUCT NAME: TADALAFILUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56018 04.05.2004

TADLIQ Market Dynamics and Financial Trajectory: Pricing, Uptake, Access, and Exclusivity-Driven Competitive Risk

Last updated: July 29, 2026

TADLIQ (tadalafil oral solution) is an ultra-limited product in the U.S. market with a narrow commercial footprint driven by (1) exclusivity and patent timing, (2) restricted prescriber adoption relative to tablet-based erectile dysfunction options, and (3) payer formulary and acquisition dynamics tied to small-volume specialty distribution. Financial trajectory is therefore shaped more by access and channel mechanics than by broad first-line uptake.

What is TADLIQ (tadalafil oral solution) and how does it compete in its drug class?

Answer: TADLIQ is tadalafil-based therapy delivered as an oral solution. In practice it competes against tadalafil tablets (and other PDE5 inhibitors) for erectile dysfunction treatment, with substitution risk driven by clinical interchangeability expectations and payer preference for lower unit cost.

Where does tadalafil oral solution sit versus tadalafil tablets?

Tadalafil is established as a PDE5 inhibitor with multiple oral solid and solution options. A solution product faces structural commercial constraints:

• Unit economics tend to be less favorable than tablets when wholesale acquisition costs and dispensing fees are normalized per therapeutic dose.
• Payer substitution frequently favors the lowest-cost therapeutically equivalent option, typically tablets unless a member has a documented barrier to solids (swallowing, dosing precision, or pediatric-adjacent rationale where applicable).
• Operational fit matters: retail pharmacies are less likely to stock niche solution SKUs than common tablet strengths, creating back-order friction and lost same-day fills.

Core demand drivers

• Formulary status (preferred vs non-preferred).
• Pharmacy network handling (in-stock rates for solution SKUs).
• Narrow clinical niche where oral solution is favored versus tablet in real-world prescribing.

Key commercial risks

• Therapeutic substitution: tadalafil oral solution is not differentiated on mechanism from tablet tadalafil.
• Concentration of sales: solution products often show sales concentrated in a smaller set of accounts and geographies.

How strong is the Orange Book and patent estate for TADLIQ, and how does it drive market timing?

Answer: The financial trajectory of TADLIQ is exclusivity-sensitive. If TADLIQ’s Orange Book listings include formulation or method-of-use patents with later expiration or pediatric exclusivity extensions, generics and authorized rivals face entry delays. If listings are limited or early-expiring, pricing pressure arrives sooner.

Patent estate mechanics that typically control revenue ramps and revenue cliffs

For brand PDE5 products, the revenue shape usually follows:

• Launch ramp: adoption within a covered population that can access the product on formulary.
• Mid-cycle resilience: weaker if generics can enter early through Paragraph IV or by relying on carve-outs.
• Endgame: revenue compression once generic entry or label-workarounds expand.

What matters for TADLIQ-specific exclusivity outcomes

• Therapeutic interchangeability accelerates substitution once any generic arrives.
• Formulation patent coverage can delay generic oral solution entry even if tadalafil API patents have expired.
• Method-of-use coverage can preserve branded use if generic labeling is constrained.

When does TADLIQ lose exclusivity and how does that change pricing and volume?

Answer: The exclusivity loss date is the main timing input for volume risk. Once barriers fall, PDE5 substitution compresses price and shifts prescriptions toward the lowest net-cost tadalafil product, typically generic solids first and solutions later if labeling and patents allow.

Revenue impact pathway after exclusivity loss

• First wave: generic entry against covered strengths leads to an immediate net price drop.
• Second wave: oral solution specific competition follows if formulation protections expire or are designed around.
• Net effect: the brand’s market share typically erodes faster than gross unit volumes because of payer switching and pharmacy substitution.

What you should model for the post-exclusivity period

• Market share trajectory: steep decline in the first 6 to 12 months after viable generic supply emerges.
• Rebate pressure: increases when payer contracts re-price around lowest acquisition cost.
• Channel concentration: solution-specific listings can shrink quickly when payer networks stop placing non-preferred solutions.

What are the strongest market dynamics: payer, pharmacy network, and wholesale behavior?

Answer: For a solution product, pharmacy network behavior and payer access are often the dominant determinants of financial trajectory.

Payer behavior that drives uptake

• Preferred tier placement drives utilization.
• Non-preferred status can still sustain sales in limited subpopulations but delays broad uptake.
• Prior authorization and quantity limits often cap volume growth even when prescribers want the product.

Pharmacy network behavior that drives fulfillment rates

• Stocking probability for niche solution SKUs is lower than for tablets.
• Back-order exposure causes missed initial demand and reduces repeat fills.
• Switch-to-tablet behavior can occur at the point of dispensing when plan rules and pharmacy policies support substitution.

Wholesale and procurement effects

• Small-volume product procurement can lead to inconsistent supply availability.
• Inconsistent availability translates into reduced prescriber trust, which can depress demand even after stock improves.

What financial trajectory should investors and brand teams expect for a tadalafil oral solution product?

Answer: The expected trajectory is characterized by (1) constrained growth due to formulary and channel limits, (2) resilience while exclusivity and access remain intact, and (3) fast price and share compression after generic solution competition becomes feasible.

Typical financial pattern for niche oral solution brands

• Early period: moderate revenue with heavy payer-by-payer variance.
• Mid period: stabilization if contract access is maintained and prescribers see consistent fulfillment.
• Late period: revenue plateau until the entry window opens, then accelerated compression.

Key KPI set that determines whether the plateau holds

• Net sales vs prescription counts (payer rebates and contract changes).
• Days on hand and in-stock rates (channel friction for solutions).
• Share of new starts vs switchers (how many scripts persist after access negotiations).

How does TADLIQ compare with other tadalafil formulations in competition and economics?

Answer: TADLIQ’s competitive position is weaker than tadalafil tablets on payer acquisition cost and dispensing convenience, but stronger where solution-specific access rules and member-specific needs support retention.

Comparison matrix (commercially relevant dimensions)

Dimension	TADLIQ (oral solution)	Tadalafil tablets (generic-ready sooner)	Competitive implication
Acquisition cost	Typically higher per dose normalization	Lower once generics dominate	Drives payer tiering decisions
Dispensing convenience	Lower (stocking/backorder risk)	Higher (retail stocking)	Affects adherence and repeat fills
Substitution likelihood	High if tablet equivalents are covered	N/A	Brand faces rapid share erosion
Access controls	More likely PA/QL	Often simpler	Limits broad uptake
Differentiation	Delivery form	Mechanism same	Solutions compete on logistics, not efficacy

What generic entry risks exist for TADLIQ and how do Paragraph IV filings change the scenario?

Answer: If TADLIQ’s Orange Book lists include solution-specific formulation patents with expiring dates and if at least one generic filer brings a Paragraph IV challenge, the brand faces a dual-risk: litigation-driven uncertainty and a faster competitive price shock once entry is authorized.

Paragraph IV entry levers that matter

• Strength of formulation patents: drives likelihood of generic design-around or settlement.
• Coordinated patent expiry: if multiple patents cluster, generic entry can be synchronized.
• Litigation settlement strategy: settlements can lock in “at-risk” entry dates or include royalty or non-expiring carve-outs.

What to monitor for entry readiness

• FDA approval and labeling readiness for tadalafil oral solution generics.
• Supply chain readiness for solution SKUs (commercial availability often determines real share loss).

What patent litigation affects TADLIQ’s market trajectory, and what outcomes matter financially?

Answer: Litigation outcomes determine the effective entry date. In tadalafil class products, once generic entry is feasible, pricing pressure and substitution typically follow quickly.

Litigation outcome categories and financial impact

• Brand wins: delayed generic entry, sustained net sales.
• Settlement: earlier than full win but often later than generic-at-risk, with defined launch dates.
• Generic wins: accelerated erosion and pricing compression.

Settlement terms that matter for revenue

• Launch calendar: hard dates for entry for specific strengths.
• Label carve-outs: restrictions that slow utilization growth.
• Exclusivity payments or royalties: may offset price erosion but usually not enough to preserve the gross net sales curve.

What is the FDA regulatory status of TADLIQ and how does pathway choice affect competitive speed?

Answer: The FDA’s regulatory posture affects competitive timelines through labeling design, exclusivity, and approval readiness. For small molecule PDE5 products, FDA competition typically tracks around generic approval pathways once patent and exclusivity barriers fall.

Regulatory factors that shape speed to market for competitors

• 505(b)(2) vs ANDA histories determine how quickly competitors can mirror or differentiate labeling.
• Bioequivalence and formulation-specific data requirements can slow solution generic entry even after patent expiry.
• Labeling parity drives payer and prescriber switching. If labeling remains fully substitutable, switching accelerates.

Which companies are likely competitive threats to TADLIQ and what market positioning do they use?

Answer: The competitive set includes tadalafil tablet generic manufacturers and any ANDA/solution entrants that can clear patent and labeling barriers for the solution form. Their positioning typically centers on lowest net price and formulary targeting rather than new clinical differentiation.

What competitive strategies usually work against a solution brand

• Aggressive PBM contracting for preferred status.
• Wide retail availability with stable inventory.
• Rapid switching programs through copay support and pharmacy substitution policies.

How should you model revenue exposure from TADLIQ’s competitive and exclusivity timeline?

Answer: Revenue exposure should be modeled as a step change at the first feasible generic entry date, with a second step if an oral solution competitor follows later.

Revenue exposure framework (high-level)

• Pre-entry: growth limited by formulary depth and channel availability.
• First entry event: sharp net price decline and market share erosion.
• Second entry event (solution-specific): additional compression and faster replacement of remaining utilization.

Key Takeaways

• TADLIQ’s market dynamics are dominated by access and channel mechanics typical of niche oral solution products, not by mechanism-level differentiation versus tablet tadalafil.
• Financial trajectory is exclusivity-sensitive: the effective generic entry date controls the revenue cliff more than routine seasonality.
• Generic risk is two-stage for solution products: tablets can pressure the brand quickly, while solution-specific competition depends on formulation and labeling patent clearance.
• Litigation and settlement outcomes determine the “effective launch calendar,” which then drives fast substitution once net price and stocking make switching easy.

FAQs

1) How does payer formulary placement impact TADLIQ net sales growth?
Preferred tier access generally produces the largest uptake lift; non-preferred placement often restricts volume and increases rebate intensity.

2) Do tadalafil tablets reduce demand for TADLIQ even before generic oral solution entry?
Yes. When covered under the same class benefit and easier to dispense, tablets typically siphon new starts and refills.

3) What is the biggest operational risk for TADLIQ as an oral solution?
Pharmacy stocking reliability and back-order friction that reduce conversion from first prescription to repeat fills.

4) How do method-of-use or formulation patents change generic entry timing for solution products?
They can delay solution-specific ANDA approvals or force label and formulation design-arounds, extending the branded period.

5) What market signal best predicts an upcoming price shock for TADLIQ?
Regulatory and litigation milestones that indicate an imminent feasible competitor launch date for the solution form.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and Approval Pathway Descriptions (ANDA/505(b)(2)). U.S. Food and Drug Administration.
3. FDA. Approved Drug Products: TADLIQ (tadalafil oral solution) product and labeling information. U.S. Food and Drug Administration.